



Lymphomas off the beaten track

Philipp Staber

Accepted: 20 December 2022

© The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2023

Lymphomas are a large and heterogenous group of malignancies of the lymphatic system. Most arise from the B-cells such as the common entities, diffuse large B-cell lymphoma or follicular lymphoma, which together represent nearly two thirds of all lymphomas. Novel treatment strategies, such as CD19-targeted chimeric antigen receptor engineered (CAR)-T cells or bispecific antibody therapies, evolved from the treatment of these B-cell malignancies and have become standard of care. But what is the current status of lymphomas that have seen less public interest in recent years? This issue of *memo* sets a focus on the advances and current status on a few of “the other” lymphoma entities.

In Hodgkin lymphoma, striking advances have been achieved in the last few decades using chemotherapy and radiation resulting in cure rates of greater than 90% even in advanced stages. Keeping high cure rates but also reducing toxicities to avoid secondary malignancies, cardiopulmonary long-term complications and to increase quality of life are the next goals. Barbara Lehner and Michael Panny [1] review the efforts of the German Hodgkin Study Group to de-escalate and discuss novel approaches including immunotherapy in the relapsed setting of Hodgkin lymphoma.

T-cell lymphomas are a group of particular medical need with a current 5-year overall survival of less than 40%. It is also an understudied group than is somehow indicated by the fact that the most common subtype is named peripheral T-cell lymphoma, “not otherwise specified” (PTCL-NOS). Alexander Pichler

summarized the latest news on T-cell lymphomas including genomic advances and describes new strategies to tackle these diseases.

The skin is a world of its own with cutaneous lymphomas demonstrating fundamental differences to systemic lymphomas. Stefanie Porkert and Julia Valencak [2] review the current diagnostic challenges, therapeutic options, and prognosis of lymphomas of the skin.

Building “highways” for lymphomas that are off beaten track is highly warranted.

Conflict of interest P. Staber declares that he/she has no competing interests.

References

Cited Literature

1. Lehner B, Panny M. Hodgkin lymphoma—How much therapy do we need? *memo*. 2022; <https://doi.org/10.1007/s12254-022-00856-z>.
2. Porkert S, Valencak J. Cutaneous lymphomas—Fast facts about an orphan disease—A short review. *memo*. 2023. <https://doi.org/10.1007/s12254-022-00863-0>

Further Reading

3. Pichler A. News on peripheral T-cell Lymphoma. *memo*. 2023. <https://doi.org/10.1007/s12254-022-00864-z>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Associate Prof. Dr. P. Staber (✉)
 Department of Medicine I, Division of Hematology
 and Hemostaseology, Medical University of Vienna,
 Währinger Gürtel 18–20, 1090 Vienna, Austria
philipp.staber@meduniwien.ac.at